Drug Trial Radar · NCT07828002
The GranStone Trial
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Oct 20, 2026
Primary completion
Mar 2029
Study completion Apr 2029
Sponsor
- Lead sponsor
- Martin Blomberg JensenAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Copenhagen University Hospital at Herlev
- First posted
- Sep 18, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will investigate whether treatment with empagliflozin or losartan can reduce the risk of kidney stone formation in patients with paraffin disease, a condition caused by the injection of paraffin oil into muscle tissue for cosmetic muscle enlargement. Paraffin disease can lead to chronic inflammation, disturbances in calcium regulation, high blood calcium levels, kidney stones, and impaired kidney function. Previous studies from Herlev-Gentofte Hospital have shown that kidney stones occur in nearly half of affected patients, while approximately one-third develop reduced kidney function. Current treatment primarily consists of high-dose corticosteroids, which can reduce blood calcium levels but cause substantial adverse effects and may not adequately control the underlying disease process. Both empagliflozin and losartan are widely used medications with documented kidney-protective effects in other chronic kidney diseases. This randomized clinical trial will evaluate whether either treatment can prevent kidney stone formation and slow kidney-related complications in patients with paraffin disease. The purpose of this study is to determine whether treatment with empagliflozin or losartan can prevent kidney stone formation and improve kidney health in patients with paraffin disease.
Conditions
- Paraffinoma
- Granuloma, Foreign-Body
Interventions
empagliflozin (Jardiance) 25 mgDrug
Once daily 25 mg tablet PO
Losartan 100 mgDrug
Once daily 100 mg tablet PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Image verified new or increased nephrolithiasis or nephrocalcinosis (from 0-24 months).Time frame: From baseline to end of follow-up at 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Division of Translational Endocrinology, Department of Endocrinology and Internal Medicine, Copenhagen University Hospital Herlev, Herlev
Herlev, Denmark · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.